CANNAINVESTOR Magazine September / October 2016 - Page 26

How the DEA’S Ruling May Affect the Retail Investor

In August, the Drug Enforcement Administration (DEA) rejected attempts to have Marijuana reclassified into a lower schedule. According to Acting Administrator Chuck Rosenberg, the decision to not reschedule marijuana was rooted in science and that "enormous weight" was placed on the conclusions by the Food and Drug Administration that marijuana has "no currently accepted medical use in treatment in the United States” and by some measures, it remains highly vulnerable to abuse as the most commonly used illicit drug across the nation. ( – August 10, 2016).

Dr. Stuart Titus, President & CEO of Medical Marijuana Inc. (OTC:MJNA), succinctly summarized a response to this ruling that reflects the opinions of a growing body of science:

Although it was disappointing to see our DEA continue their 1940’s mentality, this decision has in no way slowed down overall cannabis reform. With over half the US states allowing medical cannabis and nearly 70% of Americans favoring medical access to cannabis if recommended by a doctor – the court of public opinion is moving us toward national reform. Throughout the world, nations and their citizens are re-thinking the way we talk about cannabis and leading cannabis reform.

Choosing to ignore science and maintain these antiquated views, certainly the DEA, in concert with our FDA, does not want Americans to have federally legal access to cannabis. The cannabinoid extracts, phyto-cannabinoids, can supplement the largest self regulatory system within the human body, the endogenous cannabinoid system, thus providing health and wellness benefits. The US Government patented research via US patent # 6,630,507 describes Cannabinoids as Antioxidants and Neuroprotectants; this was applied for in 1999 and awarded in 2003. ( – August 12, 2016)

Dr. Titus further references a growing body of research that shows a direct cause and effect between Cannabis and reduced brain inflammation and beta-amyloid accumulation and this accumulation is often associated with Alzheimer’s (

From a

Retail Investor's Perspective